NURIX THERAPEUTICS, INC. Marketable Securities (Current)
NURIX THERAPEUTICS, INC. (NRIX) had Marketable Securities (Current) of $216.55 million as of 2023-08-31, per its 10-Q filed 2023-10-12.
Discontinued › Balance Sheet › Assets › Assets, Current › Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2023-10-12
- 2023-08-31: Marketable Securities, Current $216.55M.
- 2023-05-31: Marketable Securities, Current $222.22M.
- 2023-02-28: Marketable Securities, Current $243.57M.
- 2022-11-30: Marketable Securities, Current $244.67M.
| Period end | Marketable Securities, Current |
|---|---|
| 2023-08-31 | $216.55M 10-Q · filed 2023-10-12 |
| 2023-05-31 | $222.22M 10-Q · filed 2023-07-13 |
| 2023-02-28 | $243.57M 10-Q · filed 2023-04-13 |
| 2022-11-30 | $244.67M 10-Q · filed 2023-10-12 |
| 2022-08-31 | $296.92M 10-Q · filed 2022-10-06 |
| 2021-11-30 | $215.21M 10-Q · filed 2022-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |